Open an account

Mediwound

MDWD · NASDAQ

$12.10−$0.60 (−4.72%)TodayMarket closed ·
Prev close $12.70

About MDWD

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The company is headquartered in Yavne, Central(Hamerkaz) and currently employs 121 full-time employees. The company went IPO on 2014-03-20. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Employees
121
Headquarters
YAVNE, Central(HaMerkaz)
Listed
Mar 20, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
mediwound.com

MDWD key statistics

Market cap
156.21M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
76.81K
Volume
233.11K
Open price
$12.58
High today
$12.90
Low today
$12.07
52 Week high
$20.03
52 Week low
$11.84

Mediwound (MDWD) at a glance

As of Oct 20, 2026, Mediwound (MDWD) shares are priced at $12.10, giving the company a market cap of 156.21M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.07 and $12.90. The current price is 0.2% above the day's low and 6.2% below its high.

Volume so far is 233.11K shares, above the average of 76.81K shares a day.

Over the past year Mediwound has ranged from $11.84 to $20.03, and now sits 3% of the way up that range.

Mediwound met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.57 per share against an estimate of -$0.7769.

The average analyst price target is $31.28, 158.5% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $31.28
Low
$25.25
Now
$12.10
High
$37.80

MDWD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 51.3% on average.

  1. Q3 FY24: reported -$0.98 per share against an estimate of -$0.4522
  2. Q4 FY24: reported -$0.36 per share against an estimate of -$0.6197
  3. Q1 FY25: reported -$0.07 per share against an estimate of -$0.6749
  4. Q2 FY25: reported -$1.23 per share against an estimate of -$0.5831
  5. Q3 FY25: reported -$0.24 per share against an estimate of -$0.8279
  6. Q4 FY25: reported -$0.56 per share against an estimate of -$0.6443
  7. Q1 FY26: reported -$0.23 per share against an estimate of -$0.6681
  8. Q2 FY26: reported -$0.57 per share against an estimate of -$0.7769

MDWD news

  • MediWound Q2 2026 Earnings Call: Complete Transcript

  • What to Expect from MediWound's Earnings

  • Examining the Future: MediWound's Earnings Outlook

  • Earnings Preview: MediWound

  • Press releasePRNewswire

    Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Similar companies

Companies in the same industry as Mediwound

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.